Session 1: Partnerships for Global Health Impact

Chair: Nicaise Ndembi, PhD

Senior Strategy and Policy Advisor to Africa CDC Director General, Africa CDC, Addis Ababa
Associate Professor, School of Medicine, University of Maryland, MD
## Primary objective of the session and key themes to discuss

**Primary objective**

**Partnerships for Global Health Impact**

<table>
<thead>
<tr>
<th>Thematic areas to discuss</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pandemic Preparedness Prevention and Response</strong> (e.g., BRICS, API/FDF production, raw material sourcing, cost competitiveness, quality, etc.)</td>
</tr>
<tr>
<td><strong>Regulatory strengthening</strong> (e.g., harmonization, establishment of AMA, global quality standards, market authorization, etc.)</td>
</tr>
<tr>
<td><strong>Access to Finance</strong> (e.g., innovative financing solutions, deal preparation, etc.)</td>
</tr>
<tr>
<td><strong>Market shaping</strong> (e.g., pricing, demand intelligence, procurement models, incentives, etc.)</td>
</tr>
<tr>
<td><strong>Additional themes:</strong> Tech/IP, R&amp;D, Trade policy and facilitation, Innovation introduction, Transport and logistics, etc.</td>
</tr>
</tbody>
</table>
Global vaccination disparities need to be addressed via an inclusive, efficient, agile and accountable platform.
5 Ps of managing any pandemic

Knowing the:

- Politics
- Population
- Policy
- Partnership
- Pathogen
A partnership is an arrangement in which parties agree to co-operate to advance their mutual interests.
PILLAR 5: RESPECTFUL ACTION-ORIENTED PARTNERSHIPS

Africa-originated and Africa-defined priorities

Alignment with continental priorities (Agenda 2063, AfTCA)

Co-ordinated partnerships

Committed partnerships

Mutual benefits and understanding

Trusting and effective partnerships
Transformative Partnerships – work with at-scale partners to strategically drive key programmatic outcomes and capacity building
Loss of life expectancy

Zimbabwe -35
Botswana -28
South Africa -12

PEPFAR’s approach to accelerating regional manufacturing for diagnostics and ARVs

On December 16, 2022, during the Africa Leaders Summit, PEPFAR announced bold African manufacturing targets

In FY 2025:
- **15 Million** HIV Rapid Tests produced in Africa procured

In FY 2030:
- **2 Million** clients supported through procurement of African-made first line ARVs
resilient and low-carbon health systems in collaboration with MDBs, and support the work of the WHO-led Alliance for Transformative Action on Climate and Health (ATACH).

iv. Implement and prioritise tackling Antimicrobial Resistance (AMR) following the One Health approach, including through research and development, infection prevention and control, as well as antimicrobial stewardship efforts within respective national action plans through AMR and antimicrobial consumption surveillance.

v. Facilitate equitable access to safe, effective, quality-assured, and affordable vaccines, therapeutics, diagnostics, and other medical countermeasures, especially in Low-and Middle-income Countries (LMICs), LDCs and SIDS.

vi. Look forward to a successful outcome of the ongoing negotiations at the Intergovernmental Negotiating Body (INB) for an ambitious, legally binding WHO convention, agreement or other international instruments on pandemic PPR (WHO CA+) by May 2024, as well as amendments to better implement the International Health Regulations (2005).

vii. Recognize the potential role of evidence-based Traditional and Complementary Medicine in health, and take note of international efforts in this direction, including WHO’s global and collaborating centres, and clinical trial registries.
Volume guarantee for LMIC surge production

<table>
<thead>
<tr>
<th>Description</th>
<th>Guaranteeing a minimum quantity of orders for manufacturers to mitigate demand risk and facilitate scale-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key gap addressed</td>
<td>Procurement, regulatory, and scaling challenges for LMIC manufacturers</td>
</tr>
</tbody>
</table>

BII made a first-of-its-kind investment in MedAccess. MedAccess provided volume guarantees for vaccines and diagnostics that enabled LMIC manufacturers to rapidly scale.